TP53 and breast carcinoma: Our findings revealed that the median survival period for the TP53-Mutant group was 126.47 months, compared to 169.23 months for the TP53-NonMutant group, indicating a poorer prognosis associated with p53 mutations in breast cancer patients (Figure 1A).